Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1453-1458

  Hill, Sally A ^a   Tozer, Gillian M ^a   Pettit, George R ^a   Chaplin, David J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Bloodflow; Combretastatin; Necrosis; Vascular targeting

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; GROWTH RETARDATION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DIPHOSPHATES; DRUG SCREENING ASSAYS, ANTITUMOR; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PRODRUGS; STILBENES;

EID: 0036324914     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents
2. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
3. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
4. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
5. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
6. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
7. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
8. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
9. Combretastatin A4 phosphate (CA4P) reduces tumor blood flow in animals and man
10. Dynamic gadolinium-enhanced MRI of tumors: Effects of CA4P on tumor blood flow
11. Phase I study of weekly intravenous combretastatin A4 phosphate (CA4P): Pharmacokinetics and toxicity
12. Tumour vasculature as a target for cancer therapy
13. The biology of the combretastatins as vascular targeting agents
14. Tumour vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
15. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
16. Mechanisms associated with tumor vascular shut-down induced by combretastatin A4 phosphate: Intravital microscopy and measurement of vascular permeability
17. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
18. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-0-phosphate
19. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
20. ZD6126: A new agent causing selective damage of tumor vasculature
21. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs
22. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug
23. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
24. Method for the quantitative morphologic analysis of tissues
25. The influence of tumour temperature on ischemia-induced cell death: Potential implications for the evaluation of vascular mediated therapies